Home / Market News / $CTXR

$CTXR news and market catalysts

The 7 most recent market catalysts affecting $CTXR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 1 high impact 3 bullish 2 bearish Biotechnology
Nov 12, 2026 Corporate Catalyst Neutral Impact 65
Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Century Therapeutics reported a Q3 2026 net loss of $23.5 million, a significant improvement from $34.4 million in Q3 2025, primarily due to cost reductions from portfolio prioriti…
Oct 27, 2026 Corporate Catalyst Bullish Impact 75
Citius Oncology Reports Preliminary Fiscal Q4 2026 Operational Results
Citius Oncology disclosed preliminary operational results for its fiscal Q4 2026, highlighting a 120% quarter-over-quarter increase in LYMPHIR shipments to U.S. wholesalers and a r…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Citius Oncology Reports Fiscal Q4 2026 Preliminary LYMPHIR Sales Data
Citius Oncology, a subsidiary of Citius Pharmaceuticals (CTXR), reported strong preliminary sales data for its drug LYMPHIR for Q4 2026. U.S. wholesaler purchases surged by 120% qu…
Aug 17, 2026 Corporate Catalyst Bearish Impact 75
Citius Oncology shares are trading lower after the company reported worse-than-expected Q3 sales results.
This headline represents a direct corporate catalyst, specifically a negative earnings surprise. Worse-than-expected sales directly impact a company's revenue and profitability, le…
Aug 17, 2026 Corporate Catalyst Bearish Impact 75
Citius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results.
This headline represents a significant corporate catalyst for Citius Pharmaceuticals. Worse-than-expected sales directly impact a company's revenue and profitability, leading to in…
Aug 14, 2026 Corporate Catalyst Bullish Impact 85
Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate
Citius Pharma's Q3 earnings report presents a mixed bag for investors. While the company successfully narrowed its losses per share, beating analyst estimates, the substantial miss…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Citius Oncology shares are trading higher after the company reported a 78% quarter-over-quarter growth in new institutional accounts ordering LYMPHIR.
This headline represents a significant positive corporate catalyst for Citius Oncology. The 78% quarter-over-quarter growth in new institutional accounts ordering LYMPHIR demonstra…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.